Merck KGaA (OTCMKTS:MKGAF) Short Interest Update

by · The Cerbat Gem

Merck KGaA (OTCMKTS:MKGAF – Get Free Report) was the recipient of a large increase in short interest in October. As of October 15th, there was short interest totalling 237,800 shares, an increase of 22.8% from the September 30th total of 193,700 shares. Based on an average trading volume of 500 shares, the short-interest ratio is currently 475.6 days.

Wall Street Analysts Forecast Growth

Separately, The Goldman Sachs Group raised Merck KGaA to a “strong-buy” rating in a report on Thursday, September 19th.

View Our Latest Report on MKGAF

Merck KGaA Price Performance

Shares of OTCMKTS:MKGAF traded up $0.55 on Wednesday, hitting $162.98. The stock had a trading volume of 634 shares, compared to its average volume of 533. The firm’s 50 day moving average price is $178.69 and its 200-day moving average price is $176.07. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.84 and a current ratio of 1.31. Merck KGaA has a twelve month low of $144.73 and a twelve month high of $200.56. The company has a market capitalization of $21.06 billion, a price-to-earnings ratio of 23.93 and a beta of 0.96.

Merck KGaA (OTCMKTS:MKGAF – Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The company reported $1.51 EPS for the quarter. The firm had revenue of $5.76 billion for the quarter. Merck KGaA had a net margin of 12.60% and a return on equity of 10.17%. On average, equities research analysts predict that Merck KGaA will post 9.75 earnings per share for the current year.

Merck KGaA Company Profile

(Get Free Report)

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector.

Recommended Stories